{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:43:29Z","timestamp":1754599409041},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T00:00:00Z","timestamp":1464825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s10637-016-0361-8","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T03:45:31Z","timestamp":1464839131000},"page":"650-653","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy"],"prefix":"10.1007","volume":"34","author":[{"given":"Farzan","family":"Kianersi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heshmatollah","family":"Ghanbari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Naderi Beni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsaneh","family":"Naderi Beni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,2]]},"reference":[{"issue":"7","key":"361_CR1","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787\u2013794","journal-title":"Eye (Lond)"},{"key":"361_CR2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1007\/s00417-008-0874-8","volume":"246","author":"O Sawada","year":"2008","unstructured":"Sawada O, Kawamura H, Kakinoki M, Ohji M (2008) Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 246:1379\u20131381","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"361_CR3","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"issue":"1","key":"361_CR4","first-page":"32","volume":"28","author":"D Wang","year":"2014","unstructured":"Wang D (2014) Kyung Seek Choi, and Sung Jin Lee. Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab -Korean J Ophthalmol. 28(1):32\u201338","journal-title":"Serum Concentration of Vascular Endothelial Growth Factor after Bilateral Intravitreal Injection of Bevacizumab -Korean J Ophthalmol."},{"key":"361_CR5","doi-asserted-by":"publisher","unstructured":"E Rosen, A Rubowitz and J R Ferencz..Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy. Eye (2009) 23, 1479; doi:10.1038\/eye.2008.218","DOI":"10.1038\/eye.2008.218"},{"issue":"9","key":"361_CR6","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1097\/IAE.0b013e3181f57d58","volume":"30","author":"RM Tarantola","year":"2010","unstructured":"Tarantola RM, Folk JC, Boldt HC, Mahajan VB (2010) Intravitreal bevacizumab during pregnancy. Retina 30(9):1405\u20131411","journal-title":"Retina"},{"issue":"2","key":"361_CR7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.47102\/annals-acadmedsg.V39N2p143","volume":"39","author":"Z Wu","year":"2010","unstructured":"Wu Z, Huang J, Sadda S (2010) Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report. Ann Acad Med Singap 39(2):143\u2013145","journal-title":"Ann Acad Med Singap"},{"issue":"5","key":"361_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1089\/jop.2012.0067","volume":"28","author":"U Introini","year":"2012","unstructured":"Introini U, Casalino G, Cardani A, Scotti F, Finardi A, Candiani M, Bandello F (2012) Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy. J Ocul Pharmacol Ther 28(5):553\u2013555","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"361_CR9","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1055\/s-0031-1299207","volume":"229","author":"A Sarhianaki","year":"2012","unstructured":"Sarhianaki A, Katsimpris A, Petropoulos IK, Livieratou A, Theoulakis PE, Katsimpris JM (2012) Intravitreal administration of ranibizumab for idiopathic choroidal neovascularization in a pregnant woman. Klin Monatsbl Augenheilkd 229(4):451\u2013453","journal-title":"Klin Monatsbl Augenheilkd"},{"issue":"4","key":"361_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2009.01572.x","volume":"88","author":"P Petrou","year":"2010","unstructured":"Petrou P, Georgalas I, Giavaras G, Anastasiou E, Ntana Z, Petrou C (2010) Early loss of pregnancy after intravitreal bevacizumab injection. Acta Ophthalmol 88(4):e136","journal-title":"Acta Ophthalmol"},{"key":"361_CR11","doi-asserted-by":"crossref","unstructured":"Sullivan L, Kelly SP, Glenn A, Williams CP, McKibbin M1.Intravitreal bevacizumab injection in unrecognised early pregnancy. Eye (Lond). 2014 ;28(4):492\u20134","DOI":"10.1038\/eye.2013.311"},{"key":"361_CR12","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ajo.2009.06.014","volume":"148","author":"K Csaky","year":"2009","unstructured":"Csaky K, Do DV (2009) Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol 148:647\u2013656","journal-title":"Am J Ophthalmol"},{"key":"361_CR13","doi-asserted-by":"crossref","unstructured":"Fung AE, Rosenfeld PJ & Reichel E (2006): The international bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90: 1344\u20131349.","DOI":"10.1136\/bjo.2006.099598"},{"key":"361_CR14","doi-asserted-by":"crossref","unstructured":"Wu L, Martinez-Castellanos MA, Quiroz- Mercado H et al. (2007): Twelve-month safety of intravitreal injections of bevacizumab (Avastin_): results of the pan- American collaborative retina study group (PACORES). Graefes Arch Clin Exp Ophthalmol (in press).","DOI":"10.1007\/s00417-007-0660-z"},{"issue":"5","key":"361_CR15","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/bdrb.21026","volume":"95","author":"M Thorn","year":"2012","unstructured":"Thorn M, Piche-Nicholas N, Stedman D, Davenport SW, Zhang N, Collinge M (2012) Bowman CJEmbryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal fc receptor (FcRn) binding. Birth Defects Res B Dev Reprod Toxicol 95(5):363\u2013375","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"361_CR16","unstructured":"Briggs GG, Freeman RK, Yaffe SJ (2011) Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 9th ed. Wolters Kluwer\/Lippincott Williams & Wilkins, Philadelphia"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-016-0361-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0361-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-016-0361-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:57:12Z","timestamp":1678510632000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-016-0361-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,2]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["361"],"URL":"https:\/\/doi.org\/10.1007\/s10637-016-0361-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,2]]},"assertion":[{"value":"11 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Authors do not have any financial interest in the subject matter of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}